ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia
-
Published:2024-09
Issue:9
Volume:35
Page:762-768
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Eichhorst B.,
Ghia P.,
Niemann C.U.ORCID,
Kater A.P.,
Gregor M.,
Hallek M.,
Jerkeman M.,
Buske C.
Reference38 articles.
1. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Eichhorst;Ann Oncol,2021
2. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms;Alaggio;Leukemia,2022
3. The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia;Langerbeins;Blood,2022
4. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): final results of the phase 3, double-blind, placebo-controlled CLL12 trial;Langerbeins;Hematol Oncol,2023
5. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations;Furstenau;Blood,2023